Old heart drug digoxin sees new use patterns in modern heart failure care

Swedish registry data reveals how digoxin—a century-old cardiac glycoside—remains part of treatment strategies for patients with severely weakened hearts. The findings matter for pharmaceutical companies, hospital systems, and policymakers tracking which legacy drugs retain clinical value and market relevance despite newer alternatives.

Originaltitel: Digoxin use in contemporary heart failure with reduced ejection fraction: An analysis from the Swedish Heart Failure Registry (vol 8, pg 756,year 2022)